

Pitfalls in Lipid Profile Testing

血脂分析的检测陷阱

Richard Pang, PhD, FACB
彭永祥 博士

1

NCEP ATP-III



Accuracy and comprehensiveness in lipid profile testing are increasingly critical because it is used both to stratify a patient's risk for cardiovascular disease and to guide the initiation and monitoring of lipid-modifying therapy to reduce that risk

2




Lipid Profile Testing

- Total cholesterol
- HDL-C, and
- Triglycerides
- LDL-C (calculated or direct measurement)
- Apolipoproteins (apo A1, apo B)
- Lipoprotein Pattern (electrophoresis)
- Lp(a)

3



What are those Challenges?




**Analytical performance
&
Interpretation of
results**


4

Variations

- Pre-analytical
 - Patient preparation
 - Specimen collection
- Analytical
 - Standardization
 - Interferences
- Post-analytical
 - Reference ranges
 - Interpretation (clinical correlation)



5



6

Diabetes Monitoring & Lipid Profile

Lab No: 05C8014245

HKID No: 302 52 15 2 Hospital: Queen Mary Hospital
 Name: FONG, CHUN TUNG
 Hosp No: FMSY00000000 Unit/Ward/Bed: QMH/FMSY/%FMSY
 DOB: 24/03/1953 Request Loc: QMH/FMSY/%FMSY
 Sex/Age: M/52Y Requesting Dr: CHAN, PETER
 Ref: DR 3262

Collect Date : 02/09/04 01/08/05
 Collect Time : 13:45 15:00
 Request No. : C9024173 C8014245 Ref. Range Units
 Remark : F/HT DM/LLD CVD

Cholesterol	5.1	4.8		< 5.2	mmol/L
Triglycerides	2.7 H	--		< 1.7	mmol/L
HDL-C	0.70 L	0.73 L		> 1.0	mmol/L
LDL-C (calc)	3.1	--		< 3.4	mmol/L
Non-HDL-C	4.4 H	4.1		< 4.2	mmol/L
Appearance	Clear	Clear			

Drug dosage frequency Lipid 600 MG BD Lipid 600 MG BD
 贝特类降脂 (甘油三酯) 药物 Gemfibrozil 吉非贝齐

Comment: 05C8014245 Non-fasting sample unsuitable for full lipid profile measurement.

7

Humans do not possess the pathways necessary to synthesize the essential precursor fatty acid, α -linolenic acid (18:3), essential for production of the longer bioactive omega-3 fatty acids. These long-chain polyunsaturated omega-3 fatty acids must be obtained from plant sources or direct intake of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) primarily from marine or dietary source.

Omega 3 脂肪酸

Eicosapentaenoic acid (EPA) 和 Docosahexaenoic acid (DHA)

Collect Date :	22/12/04	26/12/04	07/02/05	29/03/05	01/08/05	
Collect Time :	10:00	10:45	10:30	10:30	10:00	
Request No. :	CC224085	CC264010	CC274105	CC294075	CC014131	Ref. Range Units
Remark :	F/HIGH TG DRUG	LOW K GOUT/LLD	F/HYPORKAL HIGH	F/HYPERTRIGLYCIPID/DRU DIET	Hypertlipidemia.Hyperlipidem ia.Lipid-	

Cholesterol	10.4 H	8.1 H	9.2 H	6.6 H	8.2 H	< 5.2	mmol/L
Triglycerides	16.1 H	5.2 H	4.5 H	3.3 H	7.4 H	< 1.7	mmol/L
HDL-C	1.11	1.14	1.15	1.02	1.06	> 1.0	mmol/L
LDL-C (calc)	--	--	6.0 H	4.1 H	--	< 3.4	mmol/L
LDL-C	4.4 H	5.6 H	6.4 H	--	4.9 H	< 3.4	mmol/L
Non-HDL-C	9.3 H	7.0 H	8.1 H	5.6 H	7.1 H	< 4.2	mmol/L
Appearance	Turbid	Clear	S1.Turbid	Clear	S1.Turbid		
Apo A1	1.28	--	1.39	--	--	1.20 - 2.00	g/L
Apo B	2.11 H	--	2.12 H	--	--	0.41 - 1.07	g/L

Drug dosage frequency since	Lipanthyl 200 G QD 07/09/04	Lipid 200 MG QD --	Maxepa 5 G QD 07/09/04	Maxepa 200 MG QD --	
-----------------------------	-----------------------------	--------------------	------------------------	---------------------	--

Comment: 05C8014131 Triglycerides > 4.5 Calculated-LDL not available
 05C2074105 Lipo Pattern LDL fraction was increased. VLDL fraction was also mildly elevated. Type IIb hyperlipidaemia?
 04CC264010 Triglycerides > 4.5 Calculated-LDL not available
 04CC224085 Cholesterol Verified.
 Triglycerides Verified. > 4.5 Calculated-LDL not available
 HDL-C Verified.
 Lipo Pattern An electronegative subfraction of pre-beta lipoproteins was noted. Chylomicrons also present. Fish oil supplements may interfere with the electrophoretic mobility of all lipoproteins.

Biochemist: Dr. Richard Pang
 This laboratory is accredited by CAP. Accreditation Number 71755-25
 Report Date/Time: 03/08/05 16:32 Printed on 03/08/05 16:34
 Report Destination: QMH/MED/MECM - Endocrine Clinic L2, QMH
 HAZ372QM (Rev 11/03) Page: 1/1

8

QMH Production Clinical Biochemistry ch0102 - FANGWC_V4.2.1B_R015 - IPAS To Ince Aug 3 2005 5:07PM

File Patient Request Enquiry Worksheet Support Report ADA Dictionary MIS Panel Window Help

WorkSheet - LIPD (Lipoprotein Pattern)

Lipoprotein Pattern (LIPD)

04CC224085 CHAN, YIN WAN F 44 Y F/HIGH TG DRUG

Chol 10.364 Tr1g 1.61767 HDL-Chol 1.1147 LDL 4.42 ApoA 1.28 ApoB 2.11

LIPD An electronegative subtraction of pre-beta lipoproteins was

COMDMLP

Picture for 04CC224085

Diagram: + - Edit Image Editor: + -

Seq	Description	Reportable
1	Omega-3	<input checked="" type="checkbox"/>

亞麻脂酸
Omega-3

Free fatty acids

Lane 5

Ready

Microsoft

9

Friedewald Formula

$$\text{LDL-C} = \text{Total Cholesterol} - [(\text{TG}/2.2) + \text{HDL-C}]$$

影响血脂准确测定的因素很多，如标本的来源、测定方法、仪器和试剂等，其中分析前即临床实验室进行测定之前的因素对实验结果的影响往往被忽视，应特别引起关注。

$$? \text{ TG}/2.2 = \text{VLDL-C}$$

10

Limitations

- Estimating VLDL concentration from plasma triglycerides is not valid when the triglycerides exceed 400 mg/dL (4.5 mmol/L).
- The Friedewald equation, $LDL-C = TC - HDL-C - \text{triglyceride}/5$, is used to estimate LDL cholesterol.
- The term “triglyceride/5” is used to estimate the VLDL-C concentration. In estimating VLDL from triglycerides, one assumes there are no chylomicrons in the sample and that there are no unusual lipoproteins in the sample that would alter the typical ratio of triglycerides to VLDL particles.
- It is well documented in the literature that the Friedewald equation begins to give less reliable results when the plasma triglycerides exceed 200–300 mg/dL (2.3–3.4 mmol/L), and
- It is not recommended when the triglycerides are greater than 400 mg/dL (4.5 mmol/L) because the term “triglyceride/5” no longer provides a reliable estimate of the VLDL-C.

11

Surrogate Markers

	Chylo- micron	VLDL	IDL	LDL	HDL
Density (g/mL)	<0.95	0.950– 1.006	1.006– 1.019	1.019– 1.063	1.063– 1.210
Components (% dry weight)					
Protein	2	8	15	22	40–55
Triacylglycerol	86	55	31	6	4
Free cholesterol	2	7	7	8	4
Cholesterol esters	3	12	23	42	12–20
Phospholipids	7	18	22	22	25–30
Apoprotein composition	A-I, A-II, B-48, C-I, C-II, C-I, C-II, C-III	B-100, C-I, C-II, C-III, E	B-100, C-I, C-II, C-III, E	B-100	A-I, A-II, C-I, C-II, C-III, D, E

Sources: Data from D. E. Vance and J. E. Vance (eds.), *Biochemistry of Lipids and Membranes* (Redwood City, Calif.: Benjamin/Cummings, 1985); and J. F. Mead, R. B. Alfin-Slater, D. R. Howton, and G. Popják, *Lipids* (New York: Plenum, 1986).

The typical ratio of
triglycerides to VLDL particles
= 5

12


TG/2.2 = VLDL-C

- Fasting
- Triglyceride < 4.5 mmol/L

虽然有人认为TC测定可不用禁食，但应注意饱餐后TC会有所下降；对于TG和其他脂蛋白检测则需至少禁食12小时采血。具体做法：如在采血前一天晚8点钟开始禁食（包括零食），可少量饮水。于次日早上8至10点采取静脉血，也就是应空腹12h~14h晨间取血。

Requirements

13



Lab Tests Online
A public resource on clinical lab testing from the laboratory professionals who do the testing

Peer-reviewed
Non-commercial
Patient-centered

HOME AU DE ES GR HU IT PL UK

Use the search box and menus below to quickly navigate the Lab Tests Online site:

Search Here Go TESTS CONDITIONS/DISEASES SCREENING

Direct LDL Cholesterol [email this page](#) [print this article](#)

Also known as: Direct LDL-C, Direct LDL, DLDL, LDL D
Formal name: Direct Low-density lipoprotein cholesterol
Related tests: LDL, Lipid Profile, Cholesterol, HDL, Triglycerides, ApoB

Common Questions

- 1. Why hasn't the Direct LDL-C replaced the calculated LDL-C test?**
2. **Are all LDL molecules the same?**

1. Why hasn't the Direct LDL-C replaced the calculated LDL-C test?
Calculated LDL-C is about as accurate as direct LDL-C when triglyceride levels are normal. It can be done at no additional cost when a lipid profile is performed.

[Back to top]

2. Are all LDL molecules the same?
No, LDL and other lipoprotein molecules vary in size and density. Patients with a larger percentage of small dense LDL molecules are believed to be at greater risk for atherosclerosis, than those with a higher percentage of large LDL. It is possible to separate out the different sizes of lipoprotein molecules by density (through centrifugation) or size and electrical charge (through electrophoresis). Commercial tests are available that use these separation techniques. However, the data are not clear on the clinical usefulness of these tests.

[Back to top] <http://labtestsonline.org/understanding/analytes/dldl/faq.html>

14



LDL-C

- An important clinical consideration is when two LDL-C values (calculated vs direct measurement) are available but different
- Particularly when the value is borderline, requiring a decision to treat or not to treat, such a difference would be of concern

15



Limitations

- Discrepancies between the results of calculated LDL-C and the results of the direct homogeneous LDL-C assays are primarily caused by elevated triglycerides and, to a lesser extent, by associated insulin resistance, liver or kidney diseases, and genetic defects in lipid and lipoprotein metabolism.


16

Limitations

- Dyslipidemia is a hallmark of the metabolic syndrome and insulin resistance. The underlying mechanism of the dyslipidemia of the metabolic syndrome is the altered metabolism of triglyceride-rich lipoproteins, such as VLDL and IDL remnants.
- Patients with type III hyperlipoproteinemia, characterized by cholesterol enrichment of the VLDL because of impaired clearance of remnant lipoproteins, were also reported to give erroneous values with the homogeneous assays for HDL-C and LDL-C.


17

Total Cholesterol




18

Density and Size



19



20

01CA164004

Cholestasis & Jaundice

Delta Bilirubin = 132 umol/L

TC = 31.5

TG = 4.3

HDL-C = 0.52

LDL-C = 29.0 (by calculation)

LDL-C = 5.0 (by direct method)

Apo A1 = <0.25

Apo B = 2.77



← HDL


← VLDL

← LDL

← Chylomicrons

↑ Lp-X?

21



Lipids in Health and Disease



Research

Open Access

LDL cholesterol estimation in patients with the metabolic syndrome

Irene Gazi¹, Vasilis Tsimihodimos¹, Theodosios D Filippatos¹,
Vasilios G Saougos¹, Eleni T Bairaktari², Alexandros D Tselepis³ and
Moses Elisaf*¹

Address: ¹Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece; ²Laboratory of Biochemistry, Medical School, University of Ioannina, Ioannina, Greece and ³Laboratory of Biochemistry, Department of Chemistry, University of Ioannina, Ioannina, Greece

Email: Irene Gazi - me01182@cc.uoi.gr; Vasilis Tsimihodimos - me00748@cc.uoi.gr; Theodosios D Filippatos - filtheo@hotmail.com; Vasilios G Saougos - saougos76@gmail.com; Eleni T Bairaktari - ebairak@cc.uoi.gr; Alexandros D Tselepis - atselep@cc.uoi.gr; Moses Elisaf* - egepi@cc.uoi.gr

* Corresponding author

Published: 06 April 2006

Received: 22 February 2006

Lipids in Health and Disease 2006, 5:8 doi:10.1186/1476-511X-5-8

Accepted: 06 April 2006

This article is available from: <http://www.lipidworld.com/content/5/1/8>

© 2006 Gazi et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

<http://www.lipidworld.com/content/5/1/8>

22



Friedewald (LDL-F) [4]

LDL-F = TC - HDL-C - TG/5 (in mg/dL), excluding patients with TG concentrations \geq 400 mg/dL.

Planella (LDL-P), which focuses on the inclusion of apoB levels in the estimation of LDL-C levels [21]

LDL-P = $0.41 \cdot \text{TC} - 0.14 \cdot \text{TG} + 0.66 \cdot \text{apoB} - 10.43$ (in mg/dL).

Hattori (LDL-H), an equation very similar to that proposed by Friedewald [22]

LDL-H = $0.94 \cdot \text{TC} - 0.94 \cdot \text{HDL-C} - 0.19 \cdot \text{TG}$ (in mg/dL).

AMORIS study (LDL-A), including apoA-I levels in the equation for LDL-C estimation [24]



LDL-A = $18.53 + 0.99 \cdot \text{TC} - 0.1 \cdot \text{TG} - 0.61 \cdot \text{apoA-I}$ (in mg/dL).

Wagner (LDL-W), also including apoB levels in the formula for the estimation of LDL-C concentration [20]

LDL-W = $0.358 \cdot \text{TC} + 0.776 \cdot \text{apoB} - 0.149 \cdot \text{TG}$ (in mg/dL).

Lipoprint System (LDL-L) [25, 26]

23



24

Calibrator for automated systems

759 350 10 x 3 ml

LOT 152297

2002-09

Kalibrationsserum/Calibration serum/Sérum de calibration/Suero de calibración Code: 152297
 Lösungsmittel/Solvent/Solvent/Solvente Code: 152722

Value Sheet Calibration Values

Standardized with Calibrator for automated systems
masterlot 199462

Component Bestandteil Constituant Componente Componente	Method Methode Método Método	Calibration value Kalibrationswert Valeur de calibration Valor de calibración Valor de calibración			Units Maßeinheit Unité Unidad Unidades		
		HITACHI Systems	COBAS INTEGRA	COBAS MIRA			
CHE Cholinesterase Cholinestérase Colinesterasa Colinesterase	substrate: butyrylthiocholine Substrat: Butyrylthiochin substrato: butiriltilocolina	25°C	2840 47.43			U/l µkat/l	
		30°C	3570 59.62			U/l µkat/l	
		37°C	5150 86.01	5150 86.01		U/l µkat/l	
	substrate: acetylthiocholine Substrat: Acetylthiochin substrato: acetiltilocolina	37°C	1840 30.73			U/l µkat/l	
		Also for calibration of HDL cholesterol following precipitation with phosphotungstic acid and dextran sulfate auch für die Kalibration von HDL-Cholesterin nach Fällung mit Phosphorwolframsäure und Dextransulfate Egalement pour la calibration du cholestérol HDL après précipitation par l'acide phosphotungstique et sulfate de dextran También para calibrar el colesterol HDL tras precipitación con ácido fosfotúngstico y sulfato de dextrano Anche per la calibrazione del test HDL-colesterolo dopo precipitazione mediante acido fosfotungstico ed destran-solfato		ID/MS ³	153 3.98 1.53	153 3.98 1.53	153 3.98 1.53
CHOL cholesterol total Gesamt-Cholesterin Cholesterol total Colesterol total	CHOD-PAP		Abel Kendall ⁴	149 3.87 1.49	149 3.87 1.49	149 3.87 1.49	mg/dl mmol/l g/l

25

	59.62				µkat/l
37°C	5150 86.01	5150 86.01		?	U/l µkat/l
37°C	1840 30.73				U/l µkat/l
ID/MS ³	153 3.98 1.53	153 3.98 1.53	153 3.98 1.53		mg/dl mmol/l g/l
Abel Kendall ⁴	149 3.87 1.49	149 3.87 1.49	149 3.87 1.49		mg/dl mmol/l g/l

26

- △ not to be used for factored assays./ Nicht für Tests mit Fest-Faktor Kalibrierung./ Ne pas utiliser
 Não utilizar em caso de calibração com factor fixo.
- not for use in the U.S./ Nicht für USA vorgesehen/Ne sont pas destinés aux Etats-Unis/No
 Footnotes see last page/Fußnoten siehe letzte Seite/Voir les notes en dernière page/Notas: véase la

?Merging of Roche with Boehringer Mannheim/Hitachi

27

CDC Lipid Reference Laboratory

"Most US NIH funded **epidemiological and interventional studies** performed over the last 30 years have traced their total cholesterol values to the reference methods performed at the **CDC Lipid Reference Laboratory**"

28

CDC Lipid Reference Laboratory



“The National Cholesterol Education Program (NCEP) recommends that total cholesterol measurements be traceable to the CDC reference (i.e., Abell-Kendall) method”

29

CDC Lipid Reference Laboratory

“Thus, NIST and the CAP anticipate that most manufacturers of total cholesterol reagents and calibrator materials, at least for distribution in the United States, will wish to use the CDC reference values, and NOT the NIST definitive method (ID/MS) values at this time”

Mass Spectrometer

30

LDL-C (Calculated vs Direct)

- There are **numerous pitfalls** and inaccuracies in the routine lipid profile testing.
- When two LDL-C values (calculated vs direct measurement) are available but different; particularly when the value is borderline, requiring **a decision to treat or not to treat**, such a difference would be of



31

Myths or Reality

- It is really the **number of LDL particles** and their **composition** that are critical, not just concentration of LDL-C.
- The other important issue of note is that most laboratories are measuring the **cholesterol content** of the high-density lipoprotein, that is, HDL-C, and that does not always correlate with the content of **protein moiety** in the HDL particle.



32